

## Sugar-Free Flavored Oral Syrup Vehicle



Available through your wholesaler or distributor.

ORA-Sweet® SF is a sugar-free, alcohol-free syrup vehicle used to simplify the process of flavoring and sweetening extemporaneous compounded sugar-free oral preparations. ORA-Sweet® SF allows the pharmacist to formulate elegant, sugar-free sweetened products with minimum time and maximum dependability. It is flavored with a citrus-berry blend for a highly palatable taste.

### Applications

ORA-Sweet® SF may be used alone or in combination with other agents. ORA-Sweet® SF will retain its flavoring properties when diluted up to 50% with water or suspending agents. Its versatility makes it ideal for the flavoring of:

- Pediatric suspensions
- Geriatric suspensions

### How to Use

ORA-Sweet® SF is the ideal flavoring and sweetening agent for many suspensions, but it is specially formulated to complement Padagis' suspending vehicle ORA-Plus®. ORA-Sweet® SF and ORA-Plus® can be combined in a 50/50 ratio to produce a pleasant tasting elegant suspension.

### Properties

ORA-Sweet® SF does not contain sugar or alcohol. A small amount of sodium saccharin imparts sweetness to ORA-Sweet® SF. Xanthan gum, glycerin and sorbitol contribute to both texture and good flow characteristics. ORA-Sweet® SF contains flavoring agents to increase palatability. ORA-Sweet® SF is buffered to a slightly acidic pH to help diminish degradation of medicinal agents through oxidation.

### Contains:

Purified water, glycerin, sorbitol, sodium saccharin, xanthan gum, and berry citrus flavor. Buffered with citric acid and sodium citrate. Preserved with methylparaben (0.03%), propylparaben (0.008%), and potassium sorbate (0.1%).

### Specifications

**Appearance:** Clear liquid with a slight tint

**pH range:** 4.0 - 4.4

**Taste:** Sweet citrus-berry flavor

**Osmolality:** Approximately 1979 mOsm/kg

## Compounding Examples



### ALPRAZOLAM 1 mg/mL, 120 mL<sup>2</sup>

Alprazolam 2 mg/tablet	60 tablets
ORA-Plus®	60 mL
ORA-Sweet® SF*	q.s. 120 mL

- Expiration 60 days
- Protect from light
- Shake well before using

### LABETALOL HYDROCHLORIDE 40 mg/mL, 120 mL<sup>1</sup>

Labetalol HCl 300 mg/tablet	16 tablets
ORA-Plus®	60 mL
ORA-Sweet® SF*	q.s. 120 mL

- Expiration 60 days
- Protect from light
- Shake well before using

### SPIRONOLACTONE 5 mg/mL plus HYDROCHLOROTHIAZIDE 5 mg/mL, 120 mL<sup>1</sup>

Spironolactone-Hydrochlorothiazide 25 mg/25 mg/tablet	24 tablets
ORA-Plus®	60 mL
ORA-Sweet® SF*	q.s. 120 mL

- Expiration 60 days
- Protect from light
- Shake well before using

### HYDRALAZINE HYDROCHLORIDE 4 mg/mL, 100 mL<sup>2</sup>

Hydralazine Hydrochloride 100 mg/tablet	4 tablets
ORA-Plus®	50 mL
ORA-Sweet® SF*	q.s. 100 mL

- Expiration 2 days
- Protect from light
- Shake well before using
- Store in refrigerator

### METOPROLOL TARTRATE 10 mg/mL, 120 mL<sup>1</sup>

Metoprolol Tartrate 100 mg/tablet	12 tablets
ORA-Plus®	60 mL
ORA-Sweet® SF*	q.s. 120 mL

- Expiration 60 days
- Protect from light
- Shake well before using

### VERAPAMIL HYDROCHLORIDE 50 mg/mL, 120 mL<sup>1</sup>

Verapamil HCl 80 mg/tablet	75 tablets
ORA-Plus®	60 mL
ORA-Sweet® SF*	q.s. 120 mL

- Expiration 60 days
- Protect from light
- Shake well before using

## General Directions for Compounding ORA-Sweet® SF\*/ORA-Plus® Suspensions

ORA-Sweet® SF and ORA-Plus® should be combined in a 50/50 ratio to achieve optimal formulation.

- Calculate the total amount of active ingredient and volume of solution needed to create a suspension of the proper concentration. (Calculations are provided in the examples to the left.) *It may be wise to add approximately 10% overage for compounding losses.*
- Crush tablets with a mortar and pestle to a fine powder. If the compound is already in the powder form, use the mortar and pestle to smooth out the powder.
- Add a small amount of ORA-Plus® and triturate to a thick, smooth paste. Add the remainder of the ORA-Plus® by geometric dilution. *The amount of ORA-Plus® should be 50% of the total solution.*
- Bring the suspension to a final volume using ORA-Sweet® SF\*. Mix briefly with a mortar and pestle until a uniform suspension is formed.
- Dispense in a tight, light resistant amber bottle with appropriate labeling.
- Label with an expiration date. *If the stability of the medication in an oral suspension or syrup is unknown, conservative dating is suggested.*
- Depending on the medicinal agent used, label containers “Shake Well Before Using”, “Protect From Light”, and “Keep Refrigerated”.

\*ORA-Sweet® SF may be substituted with ORA-Sweet®. Both products may be used in a 1:1 ratio with ORA-Plus®.

<sup>1</sup>American Journal of Health-System Pharmacists 1996; 53:2304-2309.

<sup>2</sup>American Journal of Health-System Pharmacists 1998; 55:1915-20.

### Contraindications

ORA-Sweet® SF is contraindicated in persons who have shown hypersensitivity to any of the listed ingredients.

### DISCLAIMER:

All information presented is intended to demonstrate the application of Padagis® vehicles in compounding. The information and examples provided in this paper have not been evaluated by the Food and Drug Administration and are provided for educational purposes only. Any information and examples provided are not intended to replace the advice of a physician or take the place of good pharmaceutical compounding practices. The preparation, dispensing, and administration of pharmaceuticals is the responsibility of licensed medical professionals and must adhere to current pharmaceutical compounding requirements and lawful practice of medicine. Padagis® assumes no liability for any injury and/or damage to persons from use of any information and/or examples contained in this document. Padagis® does not warrant against infringements of patents of third parties by reason of any uses made of the vehicles in combination with other material or in the operation of any process. Vehicle purchasers assume all risks of patent infringement by reason of any such use, combination or operation. Before compounding any prescription drug with Padagis® vehicles, please review the full prescribing information of the prescription drug for important safety information and limitations of use.